← ANALYST RATINGS · TIPRANKS
DaVita (DVA): analyst forecast and price target
Analyst consensus
Hold2 Buy2 Hold1 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $231, the highest $265, the lowest $215. The average is +23.3% from the last price of $187.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andrew Mok CFA★★★★★★★★★★#11840 · hits 51% · avg −4.8% | Barclays | $224 | Hold | +19.6% | Reiterated | 07.10.26on TipRanks 04:00 | −1.8%next day +0.6% · 5 days +3.2% | ↗ |
| David S Macdonald★★★★★★★★★★#400 · hits 63% · avg +13.2% | Truist Financial | $215 | Hold | +14.8% | Reiterated | 11.08.26on TipRanks Aug 12 22:25 | −2.6%next day +1.5% · 5 days +0.2% | ↗ |
| Ryan Langston★★★★★★★★★★#9454 · hits 47% · avg −0.6% | TD Cowen | $201 → $220+9.5% | Buy | +17.5% | Upgrade | 07.08.26on TipRanks 05:40 | +1.1%next day 0.0% · 5 days −2.4% | ↗ |
| AI PerPlexity Medical - Care FacilitiesPerPlexity SonarPro | TipRanks - PerPlexity | $273 → $246−9.9% | Hold | +31.3% | Reiterated | 05.08.26on TipRanks 13:05 | — | |
| AI Google Medical - Care FacilitiesGemini 3.1Pro | TipRanks - Google | $266 → $249−6.4% | Hold | +32.9% | Downgrade | 05.08.26on TipRanks 10:06 | — | |
| AI xAi Medical - Care FacilitiesxAI Grok-4 | TipRanks - xAI | $260 → $244−6.2% | Hold | +30.3% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI Anthropic Medical - Care FacilitiesAnthropic Opus-4.6 | TipRanks - Anthropic | $253 → $236−6.7% | Hold | +26.0% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI DeepSeek Medical - Care FacilitiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $258 → $247−4.3% | Hold | +31.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI OpenAI Medical - Care FacilitiesOpenAI 5.2 | TipRanks - OpenAI | $264 → $242−8.3% | Hold | +29.2% | Downgrade | 05.08.26on TipRanks 10:06 | — | |
| Pito Chickering★★★★★★★★★★#1500 · hits 61% · avg +9.8% | Deutsche Bank | $220 → $265+20.5% | Buy | +41.5% | Assigned | 05.08.26on TipRanks 09:25 | −17.0%next day −4.1% · 5 days −4.2% | ↗ |
| Kevin Fischbeck★★★★★★★★★★#8009 · hits 57% · avg +0.1% | Bank of America Securities | — | Sell | — | Reiterated | 05.08.26on TipRanks 07:50 | −17.0%next day −4.1% · 5 days −4.2% | ↗ |
| A.J. Rice★★★★★★★★★★#690 · hits 61% · avg +9.8% | UBS | $235 → $270+14.9% | Buy | +44.1% | Assigned | 10.07.26on TipRanks 06:25 | +1.0%next day +2.0% · 5 days +3.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering DaVita
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $239 at a price of $175 (+36.5%); now: $231 at $187 (+23.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 4 | 5 | 6 | 7 | 6 | 5 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 23.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $3.57 (from $3.39 to $4.03). Last quarter: $4.02.
Sales
Next quarter’s sales estimate — $3.5B (from $3.5B to $3.6B). Last quarter: $3.6B.
Best top-analyst consensus in the sector · Healthcare
About DaVita
- CEO: Javier J. Rodriguez
- Employees: 78,000
- 2000 16th Street, Denver, CO, 80202, US
- www.davita.com
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Data from the stock’s TipRanks forecast page, read 136 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗